Human Psychopharmacology-Clinical and Experimental

Papers
(The H4-Index of Human Psychopharmacology-Clinical and Experimental is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans22
N,N‐dimethyltryptamine and Amazonian ayahuasca plant medicine22
Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment‐resistant depression18
Efficacy of amisulpride for depressive symptoms in individuals with mental disorders: A systematic review and meta‐analysis14
Potential processes of change in MDMA‐Assisted therapy for social anxiety disorder: Enhanced memory reconsolidation, self‐transcendence, and therapeutic relationships13
Anabolic androgenic steroids used as performance and image enhancing drugs in professional and amateur athletes: Toxicological and psychopathological findings13
High‐dose Vitamin B6 supplementation reduces anxiety and strengthens visual surround suppression13
Efficacy of naltrexone in borderline personality disorder, a retrospective analysis in inpatients12
A phase 1 double‐blind, placebo‐controlled study of zuranolone (SAGE‐217) in a phase advance model of insomnia in healthy adults12
Effects of ayahuasca on the endocannabinoid system of healthy volunteers and in volunteers with social anxiety disorder: Results from two pilot, proof‐of‐concept, randomized, placebo‐controlled trials12
Comparison of potential psychiatric drug interactions in six drug interaction database programs: A replication study after 2 years of updates12
Ayahuasca may help to improve self‐compassion and self‐criticism capacities11
Elevated serum levels of TNF‐α, IL‐6, and IL‐18 in chronic methamphetamine users11
Effect of crocin versus fluoxetine in treatment of mild to moderate obsessive‐compulsive disorder: A double blind randomized clinical trial11
0.022364854812622